Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model


06 Mar 2023


Cocktail & Poster Display session


Samart Phuwapraisirisan


Annals of Oncology (2023) 8 (1suppl_2): 100898-100898. 10.1016/esmoop/esmoop100898


S. Phuwapraisirisan1, P. Ingrungruanglert2, N. Israsena2, C. Sahakitrungruang1, S. Malakorn1

Author affiliations

  • 1 Surgery, Chulalongkorn University, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 2 Excellence Center For Stem Cells And Cell Therapy, Chulalongkorn University, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH


This content is available to ESMO members and event participants.

Abstract 101P


Identifying locally advanced rectal cancer patients responsive to chemoradiotherapy before surgery remains a challenge. Patient-derived organoid (PDOs) biobanks may potentially predict therapeutic response to chemotherapy and radiation. We conducted a prospective clinical trial with treatment-naive rectal cancer patients and matched patient-derived tumor organoids to determine whether a correlation exists between experimental results obtained after irradiation in patients and organoids.


Between May 2019 and June 2021, 55 patients who were diagnosed with pathologically confirmed mid-to-lower rectal cancer were prospectively enrolled. High-risk patients with locally advanced rectal cancer (LARC) indicating neoadjuvant chemoradiotherapy (NCRT) according to ESMO guidelines. Pre-NCRT rectal cancer tissue samples were obtained. Tumor organoids were isolated and cultured. The mutational status of tissues and organoids was analyzed. Long course NCRT with total dose of 50.4-55.8Gy in 28 to 31 fractions was performed. Infusional 5-FU or oral capecitabine or XELOX was administered. Radical surgeries performed at 8-12 weeks after completing radiation. Pathologic response after NCRT was evaluated using the tumor regression grade (TRG) system. To validate the response of PDTOs to irradiation in vitro, we performed a radiation dose-dependent (0, 2, 4,6 and 8Gy) survival analysis of 37 PDOs.


PDOs radiation dose-viability curves showed substantial inter-patient heterogeneity in radiosensitivity. PDOs from post-NCRT tissues displayed higher radioresistance than those from treatment-naïve specimens. We observed strong correlation between each group and clinical outcome post NCRT. 6 of 7 patients (85.7%) whose PDOs assigned to PDOs-radioresistant group showed poor response (TRS score = 2) after NRCT, while 4 of 7 patients (57.1%) whose PDOs assigned to PDOs-radiosensitive group displayed good response (TRS = 1) and 2 of 7 patients (28.5 %) showed complete response (TRS = 0).


Our data provide promising evidence for correlations between in vitro organoid responses and clinical responses to NCRT in locally advanced rectal cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Faculty of Medicine, Chulalongkorn University.


C2F Funding, Chulalongkorn University.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.